Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Metagenomi Therapeutics, Inc.MGX · Entity 7270 | See Remarks | April 01, 2024 | April 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Metagenomi Therapeutics, Inc.
Report date April 01, 2024 · Filed April 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 93,892 |
Reported balance
After 2024-04-01 transaction · row 1
1 source rowRow 1 · 2024-04-01 · Grant · Acquired 6,931 · Balance 93,892 F1: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.82 · Expires 2034-03-31 | Direct | 29,145 |
Reported balance
After 2024-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-01 · Grant · Acquired 29,145 · Balance 29,145 F2: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F2: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2024 Filed Apr 4, 2024 00:18 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 29,145 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000950170-24-041483 · ownership.xml · derivative · entry 2 Delaney Simren · CIK 0001995684 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,145 Underlying: Common Stock · 29,145 shares Expires 2034-03-31 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:18 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 6,931 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-041483 · ownership.xml · nonDerivative · entry 1 Delaney Simren · CIK 0001995684 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,892 F1 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.